BioSpace News Archive

Guardant Health, Inc. announces that the U.S. Food and Drug Administration has approved Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling, in patients with any solid malignant neoplasm.

BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces that CSL Behring, a leading global biotechnology company focused on discovering, developing and delivering medicines for people with rare and serious diseases, becomes the fifth partner in BaseLaunch Phase II, the next phase in BaseLaunch’s company building activities.

The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

J-STAR Research, Inc. (J-Star) and XtalPi will be hosting the 2020 Pharmaceutical Crystallization Summit on October 7th and 8th, 2020, online (live).

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the pricing of an underwritten offering of $1.250 billion aggregate principal amount of senior unsecured notes due 2030 (the “2030 notes”) and $750 million aggregate principal amount of senior unsecured notes due 2050 (the “2050 notes” and, together with the 2030 not

Cutera, Inc. (NASDAQ: CUTR ) (“Cutera” or the “Company”), a leading provider of energy-based aesthetic systems for practitioners worldwide, today announced that Dave Mowry, Chief Executive Officer, will present at the 40 th Annual Canaccord Genuity Growth Conference at 3:00 p.m. ET on Thursday, August 13, 2020. A live webcast of the presentation will be accessible through the “Investors” section of the Company’s w

Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 13,000 shares of the Company’s common stock with an exercise price of $23.08 per share, the closing price of Assembly’s common stock on August 3, 2020.

Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it has added two new independent directors to its board who bring deep commercial and strategic experience to the company: Suzanne Sawochka Hooper, the former executive vice president and general counsel of Jazz Pharmaceuticals

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2020 and provided business highlights. “We are thrilled with the strong progress across our pipeline, the continued productivity across the company despite th